1-6 of 6
Daniel Lysak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, Andrew Aw, Malgorzata Wach, Arpad Illes, Alessandra Tedeschi, Carolyn Owen, Alan P Skarbnik, Daniel Lysak, Ki-Seong Eom, Martin Šimkovič, Miguel Arturo Pavlovsky, Arnon P. Kater, Barbara F. Eichhorst, Kara Miller, Veerendra Munugalavadla, Ting Yu, Marianne de Borja, Paolo Ghia
Journal: Blood
Blood (2024) 144 (Supplement 1): 1009.
https://doi.org/10.1182/blood-2024-200701
Published: 2024
Journal Articles

Molecular Mechanisms Underlying Abnormal Activation of T Cells in Idiopathic Aplastic Anemia and Hypoplastic Myelodysplastic Neoplasms

Zuzana Lenertová, Monika Kaisrlikova, David Kundrat, Hana Votavova, Jitka Vesela, Iva Trsová, Sarka Ransdorfova, Iuri Marinov, Tomas Prochazka, Daniel Lysak, Anna Jonasova, Jaroslav Čermák, Monika Belickova
Journal: Blood
Blood (2023) 142 (Supplement 1): 1342.
https://doi.org/10.1182/blood-2023-181713
Published: 2023
Journal Articles

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Jana Mihalyova, Anna Panovska, Martin Simkovic, Peter Turcsanyi, Martin Spacek, Martin Brejcha, Daniel Lysak, Heidi Mocikova, Sarka Pavlova, Marika Chrapava, Jana Zuchnicka, Yvona Brychtova, Pavel Vodarek, Renata Urbanova, Tereza Likarova, Jitka Malcikova, Tereza Jurkova, Klara Lancova, Lucie Bezdekova, Tomas Papajik, Jana Baranova, Tomas Arpas, Sarka Pospisilova, Lukas Smolej, Michael Doubek
Journal: Blood
Blood (2023) 142 (Supplement 1): 6542.
https://doi.org/10.1182/blood-2023-181249
Published: 2023
Journal Articles

Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases

Michael Doubek, Mudr. Lukas Smolej, Martin Šimkovič, Anna Panovska, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Emmanuel Bachy, Lucile Baseggio, Emmanuelle Ferrant, Joris Diels, Jedelyn Cabrieto, Lasse Nielsen, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4679.
https://doi.org/10.1182/blood-2021-147927
Published: 2021
Journal Articles

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Šimkovič, Iryna Kriachok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Min Hui Wang, Ting Yu, Paolo Ghia
Journal: Blood
Blood (2021) 138 (Supplement 1): 393.
https://doi.org/10.1182/blood-2021-146570
Published: 2021
Journal Articles

Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases

Gilles Salles, MD PhD, Lukas Smolej, MD PhD, Emmanuel Bachy, Lucile Baseggio, MD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Wafae Iraqi, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Martin Spacek, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Michael Doubek, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5342.
https://doi.org/10.1182/blood.V130.Suppl_1.5342.5342
Published: 2017